Bulletin du Cancer

Papers
(The H4-Index of Bulletin du Cancer is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
An overview of autophagy: Mechanism, regulation and research progress179
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer30
COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obs27
Mucosal-associated invariant T (MAIT) cells, a new source of universal immune cells for chimeric antigen receptor (CAR)-cell therapy17
Medicinal plants used by patients to fight cancer in northwestern Algeria16
Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab15
CAR-T cells, from principle to clinical applications15
COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children an14
Vaccination contre le virus de l’hépatite B et prévention du cancer du foie10
Role of H2B mono-ubiquitination in the initiation and progression of cancer10
Treating cancer patients in times of COVID-19 pandemic: A virtual women cancers multidisciplinary meeting experience10
Mécanismes de la lymphopénie radio-induite et implications thérapeutiques10
Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO10
0.06702709197998